Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Acquisition extends Resonant's European footprint and adds specialized calibration expertise, IOR/EOR reach, and partner ...

(PFP), has resubmitted the tabelecleucel Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). ...

IM-1340 incorporates Immunome's proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed ...

Results mark the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatology. Tulisokibart was designed ...

Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal ...

Marks the Completion of NanoACTIV Integration Across the Company’s Entire Additively Manufactured and Wrought Titanium Spinal ...

Agreement provides long-term expanded access to Catalent's fast-dissolving (Zydis ®) tablet formulation technology. Supply ...

Ebvallo, which Pierre Fabre Pharmaceuticals and Atara Biotherapeutics are proposing to treat a posttransplant complication, ...

(Nasdaq: KARD) (“Kardigan”), a precision cardiovascular company, announced today the appointment of Kristin Reinke to its ...

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its ...

Of the 38 companies receiving incentives, 31 will expand outside of Boston and Cambridge. Still, Boston and Cambridge are ...